Shares of Avanos Medical Inc (NYSE:AVNS) have received a consensus recommendation of “Hold” from the nine analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $35.00.
Several brokerages recently issued reports on AVNS. Barclays reaffirmed a “sell” rating and set a $32.00 price objective on shares of Avanos Medical in a report on Thursday, February 27th. Morgan Stanley reduced their price objective on Avanos Medical from $36.00 to $32.00 and set an “underweight” rating for the company in a report on Tuesday, December 17th. Stephens reduced their price objective on Avanos Medical from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Monday. TheStreet cut Avanos Medical from a “c-” rating to a “d+” rating in a report on Monday, February 10th. Finally, ValuEngine raised Avanos Medical from a “hold” rating to a “buy” rating in a report on Tuesday, February 25th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVNS. Meeder Asset Management Inc. raised its holdings in shares of Avanos Medical by 17,283.3% in the fourth quarter. Meeder Asset Management Inc. now owns 2,086 shares of the company’s stock worth $70,000 after acquiring an additional 2,074 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Avanos Medical in the fourth quarter worth $151,000. Advisory Services Network LLC raised its holdings in shares of Avanos Medical by 293.1% in the fourth quarter. Advisory Services Network LLC now owns 4,729 shares of the company’s stock worth $159,000 after acquiring an additional 3,526 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Avanos Medical by 9.3% in the fourth quarter. Amalgamated Bank now owns 7,935 shares of the company’s stock worth $267,000 after acquiring an additional 673 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Avanos Medical in the fourth quarter worth $274,000. 96.71% of the stock is owned by institutional investors.
Avanos Medical (NYSE:AVNS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.02. The firm had revenue of $189.80 million during the quarter, compared to analysts’ expectations of $178.58 million. Avanos Medical had a positive return on equity of 3.99% and a negative net margin of 6.58%. Avanos Medical’s revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.30 earnings per share. Research analysts anticipate that Avanos Medical will post 1.1 EPS for the current year.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Featured Story: How do analysts define an oversold condition?
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.